Renovascular Hypertension Induces Myocardial Mitochondrial Damage, Contributing to Cardiac Injury and Dysfunction in Pigs With Metabolic Syndrome.
blood pressure
cardiac dysfunction
hypertension
metabolic syndrome
mitochondria
renovascular hypertension
Journal
American journal of hypertension
ISSN: 1941-7225
Titre abrégé: Am J Hypertens
Pays: United States
ID NLM: 8803676
Informations de publication
Date de publication:
11 03 2021
11 03 2021
Historique:
received:
09
07
2020
revised:
15
10
2020
accepted:
01
12
2020
pubmed:
6
12
2020
medline:
30
11
2021
entrez:
5
12
2020
Statut:
ppublish
Résumé
Renovascular hypertension (RVH) often manifest with metabolic syndrome (MetS) as well. Coexisting MetS and hypertension increases cardiovascular morbidity and mortality, but the mechanisms underlying cardiac injury remain unknown. We hypothesized that superimposition of MetS induces myocardial mitochondrial damage, leading to cardiac injury and dysfunction in swine RVH. Pigs were studied after 16 weeks of diet-induced MetS with or without RVH (unilateral renal artery stenosis), and Lean controls (n = 6 each). Systolic and diastolic cardiac function were assessed by multidetector CT, and cardiac mitochondrial morphology (electron microscopy) and myocardial function in tissue and isolated mitochondria. Body weight was similarly higher in MetS groups vs. Lean. RVH groups achieved significant stenosis and developed hypertension. Mitochondrial matrix density and adenosine triphosphate production were lower and H2O2 production higher in RVH groups vs. Lean and MetS. Lean + RVH (but not MetS + RVH) activated mitophagy, which was associated with decreased myocardial expression of mitophagy-related microRNAs. MetS groups exhibited higher numbers of intermitochondrial junctions, which could have prevented membrane depolarization/activation of mitophagy in MetS + RVH. Cardiac fibrosis, hypertrophy (increased left ventricular muscle mass), and diastolic function (decreased E/A ratio) were greater in MetS + RVH vs. Lean + RVH. MetS+RVH induces myocardial mitochondrial damage and dysfunction. MetS + RVH failed to activate mitophagy, resulting in greater cardiac remodeling, fibrosis, and diastolic dysfunction. Mitochondrial injury and impaired mitophagy may constitute important mechanisms and therapeutic targets to ameliorate cardiac damage and dysfunction in patients with coexisting MetS and RVH.
Sections du résumé
BACKGROUND
Renovascular hypertension (RVH) often manifest with metabolic syndrome (MetS) as well. Coexisting MetS and hypertension increases cardiovascular morbidity and mortality, but the mechanisms underlying cardiac injury remain unknown. We hypothesized that superimposition of MetS induces myocardial mitochondrial damage, leading to cardiac injury and dysfunction in swine RVH.
METHODS
Pigs were studied after 16 weeks of diet-induced MetS with or without RVH (unilateral renal artery stenosis), and Lean controls (n = 6 each). Systolic and diastolic cardiac function were assessed by multidetector CT, and cardiac mitochondrial morphology (electron microscopy) and myocardial function in tissue and isolated mitochondria.
RESULTS
Body weight was similarly higher in MetS groups vs. Lean. RVH groups achieved significant stenosis and developed hypertension. Mitochondrial matrix density and adenosine triphosphate production were lower and H2O2 production higher in RVH groups vs. Lean and MetS. Lean + RVH (but not MetS + RVH) activated mitophagy, which was associated with decreased myocardial expression of mitophagy-related microRNAs. MetS groups exhibited higher numbers of intermitochondrial junctions, which could have prevented membrane depolarization/activation of mitophagy in MetS + RVH. Cardiac fibrosis, hypertrophy (increased left ventricular muscle mass), and diastolic function (decreased E/A ratio) were greater in MetS + RVH vs. Lean + RVH.
CONCLUSIONS
MetS+RVH induces myocardial mitochondrial damage and dysfunction. MetS + RVH failed to activate mitophagy, resulting in greater cardiac remodeling, fibrosis, and diastolic dysfunction. Mitochondrial injury and impaired mitophagy may constitute important mechanisms and therapeutic targets to ameliorate cardiac damage and dysfunction in patients with coexisting MetS and RVH.
Identifiants
pubmed: 33277650
pii: 6024518
doi: 10.1093/ajh/hpaa202
pmc: PMC7951049
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-182Subventions
Organisme : NHLBI NIH HHS
ID : R25 HL092621
Pays : United States
Informations de copyright
© American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Stem Cell Res Ther. 2015 Jan 19;6:7
pubmed: 25599803
FEBS Lett. 2018 Mar;592(5):793-811
pubmed: 29364506
Nat Rev Cardiol. 2017 Apr;14(4):238-250
pubmed: 28004807
Hypertension. 2019 Jun;73(6):e87-e120
pubmed: 30866654
J Biomed Sci. 2011 Jun 01;18:35
pubmed: 21631941
J Cardiovasc Transl Res. 2010 Aug;3(4):374-83
pubmed: 20559783
J Hypertens. 2019 Oct;37(10):2061-2073
pubmed: 31465309
Biochem Biophys Res Commun. 2016 Oct 14;479(2):343-350
pubmed: 27644883
Circ Res. 2011 Apr 1;108(7):837-46
pubmed: 21311045
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14315-20
pubmed: 20656937
Obesity (Silver Spring). 2015 Feb;23(2):399-407
pubmed: 25627626
PLoS One. 2012;7(11):e48925
pubmed: 23145024
Nat Commun. 2015 Feb 17;6:6259
pubmed: 25687472
J Hypertens. 2014 Jan;32(1):154-65
pubmed: 24048008
J Lab Clin Med. 2005 Sep;146(3):160-73
pubmed: 16131455
Endocrinol Metab Clin North Am. 2004 Jun;33(2):351-75, table of contents
pubmed: 15158523
J Mol Cell Cardiol. 1992 Jul;24(7):669-81
pubmed: 1404407
J Am Soc Nephrol. 1999 Jul;10(7):1455-65
pubmed: 10405201
J Cell Biol. 2010 Nov 29;191(5):933-42
pubmed: 21115803
Eur Heart J. 2014 Dec 7;35(46):3258-66
pubmed: 25385092
Basic Res Cardiol. 2020 Jan 14;115(2):16
pubmed: 31938859
Hypertension. 1995 Apr;25(4 Pt 1):517-23
pubmed: 7721392
Exp Biol Med (Maywood). 2002 Oct;227(9):837-42
pubmed: 12324666
Sci Rep. 2016 Aug 10;6:30610
pubmed: 27506553
J Am Soc Nephrol. 2015 Sep;26(9):2074-80
pubmed: 25868641
Int J Cardiol. 2011 Sep 1;151(2):143-7
pubmed: 20542341
Curr Top Dev Biol. 2007;77:113-55
pubmed: 17222702
J Biol Chem. 2012 Jun 1;287(23):19094-104
pubmed: 22505714
Int J Biochem. 1980;12(1-2):17-22
pubmed: 7399019
Am J Physiol Heart Circ Physiol. 2015 Feb 1;308(3):H183-92
pubmed: 25437922
Cell Transplant. 2018 Jul;27(7):1080-1095
pubmed: 29954220
Eur Heart J. 2015 Oct 14;36(39):2630-4
pubmed: 26242711
Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H669-H680
pubmed: 29196345
Circ Res. 2018 Jul 20;123(3):356-371
pubmed: 29898892
Cardiovasc Res. 2018 Mar 01;114(3):431-442
pubmed: 29267873
J Mol Cell Cardiol. 2013 Sep;62:51-7
pubmed: 23672826
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9572-7
pubmed: 21606348
Biol Chem. 2012 Jul;393(7):547-64
pubmed: 22944659
J Vasc Surg. 2010 Apr;51(4):926-32
pubmed: 20022208
J Am Heart Assoc. 2016 May 31;5(6):
pubmed: 27247333